{"id":"W4245954238","doi":"10.1016/s0305-7372(04)00144-6","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆, ☆, ☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Oncology; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer research; Cancer; Cisplatin; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008606894,0.0003131241,0.001937317,0.0002823892,0.0003090907,0.0005344875,0.000277031,0.0008609478,0.004926184],"category_scores_gemma":[0.002016698,0.0001551668,0.001836751,0.0003424301,0.0002852002,0.0005734876,0.0002122263,0.0008854264,0.0004825017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005607131,"about_ca_system_score_gemma":0.000478409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001387891,"about_ca_topic_score_gemma":0.006457522,"domain_scores_codex":[0.9995342,0.0001718313,0.00004044457,0.0000641805,0.00008187522,0.0001075379],"domain_scores_gemma":[0.9994317,0.0001905344,0.0001566285,0.00002951025,0.00004394189,0.0001475676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3232931,0.002609751,0.0623669,0.002832562,0.008112031,0.0008976233,0.0001717816,0.001018831,0.01045843,0.0002657847,0.03304126,0.554932],"study_design_scores_gemma":[0.1294503,0.1433454,0.6472037,0.001057494,0.01864968,0.003400068,0.0002752551,0.001577444,0.005245095,0.0008342415,0.04884807,0.0001131687],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.8907216,0.08763315,0.0001731634,0.006858089,0.001548034,0.0001550934,0.001640141,0.0001440221,0.01112681],"genre_scores_gemma":[0.9848305,0.01131916,0.0001494056,0.001132784,0.000568951,0.00005448062,0.0005512598,0.00001068825,0.001382708],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.004926184,"threshold_uncertainty_score":0.01647967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01387739812871515,"score_gpt":0.3274173636403254,"score_spread":0.3135399655116102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}